Greg Harrison
Stock Analyst at B of A Securities
(4.42)
# 289
Out of 5,172 analysts
104
Total ratings
54.43%
Success rate
19.77%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Maintains: Buy | $46 → $51 | $24.07 | +111.88% | 3 | Mar 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $454.00 | +22.91% | 8 | Feb 13, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $34 | $27.86 | +22.04% | 9 | Dec 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $12.84 | +133.64% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $524.28 | -11.69% | 5 | Sep 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $26.84 | +15.50% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $8.18 | +144.50% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $68.54 | -16.84% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $312.17 | +44.15% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.42 | +2,504.17% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $6.63 | +427.90% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $40.53 | +35.70% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $4.14 | +358.94% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $36.41 | +1.62% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $10.96 | +137.23% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $17.21 | +16.21% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.46 | +2.74% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $24.63 | +62.40% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $58.17 | +28.93% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.23 | +36.05% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $33.51 | -64.19% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.33 | +352.22% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.34 | +541.03% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $11.00 | -72.73% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.92 | +7,508.70% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $14.17 | +281.09% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $72.22 | +24.62% | 5 | Mar 14, 2022 |
Mineralys Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $46 → $51
Current: $24.07
Upside: +111.88%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $454.00
Upside: +22.91%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $34
Current: $27.86
Upside: +22.04%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $12.84
Upside: +133.64%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $524.28
Upside: -11.69%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $26.84
Upside: +15.50%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $8.18
Upside: +144.50%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $68.54
Upside: -16.84%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $312.17
Upside: +44.15%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.42
Upside: +2,504.17%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $6.63
Upside: +427.90%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $40.53
Upside: +35.70%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $4.14
Upside: +358.94%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $36.41
Upside: +1.62%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $10.96
Upside: +137.23%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $17.21
Upside: +16.21%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.46
Upside: +2.74%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $24.63
Upside: +62.40%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $58.17
Upside: +28.93%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.23
Upside: +36.05%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $33.51
Upside: -64.19%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.33
Upside: +352.22%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.34
Upside: +541.03%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $11.00
Upside: -72.73%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.92
Upside: +7,508.70%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $14.17
Upside: +281.09%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $72.22
Upside: +24.62%